Transplantation Infection Clinical Trial
Official title:
CMV Infection and Immune Intervention After Haploidentical Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early complication of allo-HSCT. Its high incidence and poor prognosis can cause a series of terminal organ diseases such as CMV pneumonia, encephalitis, and enteritis,which seriously affecting the prognosis of patients post allo-HSCT. Our data show that rapid reconstruction of NK cells after transplantation can reduce the incidence of CMV infection. Patients with a rapid reconstruction of NKG2C after transplantation have a low CMV infection rate, and patients with strong secretion of IFN-gamma of NK after transplantation have low CMV infection. Our previous research showed that trophoblast cells transfected with IL-21 and 4-1BBL can achieve a large number of clinical-grade expansion of NK cells (mIL-21 / 4-1BBL NK cells), and mIL-21 / 4-1BBL NK cells It is safe to treat patients with minimal residual disease (MRD) positive AML after transplantation, and can induce MRD to turn negative. Previous studies have shown that adoptive infusion of expanded NK cells after haplotype transplantation is safe and can improve the functional reconstruction of NK cells. Therefore, we hypothesized that the infusion of NK cells can improve the antiviral capacity of NK cells, thereby effectively reducing the CMV infection. Incidence.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2021 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) or myeloma or lymphoma undergoing haploidentical allogeneic stem cell transplantation 2. No CMV infection by 20 days ± 3 days after transplantation 3. No active acute GVHD by 20 days ± 3 days after transplantation 4. The dose of prednisolone was less than 0.5mg / kg / d within 72 hours before and after infusion of NK cells 5. Prior to transplantation, the CMV IgG of the recipient and donor were positive, and the recipient had a suitable donor to expand NK cells. 6. Patient age 16-65 years 7. Donor age 16-65 years 8. Patient Karnofsky score> 70% 9. Estimated survival> 3 weeks 10. Patient agrees to participate in study Exclusion Criteria: 1. Participants in any other clinical trials within 1 month before enrollment 2. Active infection 3. HBV or HCV or HIV carriers 4. With moderate to severe renal dysfunction (blood creatinine> 130umol / L) and / or liver dysfunction (total bilirubin> 34umol / L, ALT, AST> 2 times the upper limit of normal) before NK infusion 5. Researchers do not consider it appropriate to participate in this trial. |
Country | Name | City | State |
---|---|---|---|
China | Peking University Institute of Hematology | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cumulative incidence of CMV infection post transplantation | Whether to reduce the incidence of CMV infection in patients post haploidentical transplantation | within 180 days post transplantation | |
Secondary | Cumulative incidence of refractory CMV infection post transplantation | Whether to reduce the incidence of refractory CMV infection in patients post haploidentical transplantation | within 180 days post transplantation | |
Secondary | Cumulative incidence of CMV disease post transplantation | Whether to reduce the incidence of CMV disease in patients post haploidentical transplantation | within 180 days post transplantation | |
Secondary | Enhanced anti-CMV function of reconstituted NK cells | Whether to enhance the anti-CMV function of reconstituted NK cells | within 180 days post transplantation | |
Secondary | cumulative incidence of TRM | Whether to reduce the incidence of transplantation related mortality in patients post haploidentical transplantation | within 180 days post transplantation | |
Secondary | cumulative incidence of overall survival | Whether to increase the incidence of overall survival in patients post haploidentical transplantation | within 180 days post transplantation | |
Secondary | cumulative incidence of disease free survival | Whether to increase the incidence of disease free survival in patients post haploidentical transplantation | within 180 days post transplantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05047406 -
Bacillus Clausii in Liver Transplantation
|
Phase 2 | |
Completed |
NCT02463214 -
Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients
|
N/A | |
Recruiting |
NCT05198570 -
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
|
||
Completed |
NCT01808456 -
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
|
Phase 4 | |
Suspended |
NCT01301118 -
Graft Take and Microbiology in Burns
|
N/A | |
Completed |
NCT00610961 -
Induction Related BK Viremia in Renal Transplant Patients
|
Phase 4 | |
Recruiting |
NCT05215327 -
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
|
Phase 2 | |
Recruiting |
NCT05193058 -
Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
|
||
Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02811835 -
TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN)
|
N/A | |
Completed |
NCT01471444 -
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Enrolling by invitation |
NCT01349738 -
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
|
N/A | |
Terminated |
NCT00473824 -
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
|
Phase 2 | |
Completed |
NCT00177801 -
Organ Transplant Infection Prevention and Detection Project
|
Phase 4 | |
Completed |
NCT01276457 -
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
|
Phase 3 | |
Completed |
NCT02328963 -
Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
|
Phase 4 | |
Active, not recruiting |
NCT01295645 -
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
|
Phase 2 | |
Completed |
NCT02329808 -
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
|
||
Completed |
NCT01471067 -
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT04579471 -
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
|